Fig. 7: PRMT5 inhibition sensitizes breast cancer cells to AKT inhibitor and chemotherapeutic agents.
From: PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis
a, b Breast cancer cells were treated with DMSO, 0.5 μM GSK3326595 (GSK), 0.5 μM MK2206 (MK), or both (GSK + MK) for 4 days before examining cell viability. c, d Breast cancer cells were treated with DMSO, 0.5 μM GSK, 0.25 μM etoposide (Eto), or both (GSK + Eto) for 4 days before examining cell viability. e, f Breast cancer cells were treated with DMSO, 0.5 μM GSK, 2 μM cisplatin (Cis), or both (GSK + Cis) for 4 days before examining cell viability. g Proposed model to describe the role of AKT1-R391 methylation on promoting PI3K-dependent AKT activation. Statistical significance was determined by two-tailed Student’s t-test in a–f. Statistical source data are provided in Source Data file.
